Speaker(s): 

Mark Antonio, CRNA, Staff Member, Geisinger - has nothing to disclose.

Ted Lengyel, CRNA, Staff Member, Geisinger - has nothing to disclose. 

Moderator(s): 

Kristy Voytek, MD, Regional Chief of Anesthesia, Geisinger - has nothing to disclose. 

Learning Objectives:

At the conclusion of this session, the participant should be able to:  

1. Discuss mechanism of action of Sugammadex
2. Explore the efficiency of Sugammadex in Patients with ESRD
3. Describe the pharmacometrics of Sugammadex in patients with ESRD
4. List safety related results of Sugammadex in patients with ESRD
5. Discuss the use of Sugammadex in renal transplantation patients

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Kristy Voytek, MD, Maria Mcgraw, CRNA, and Gary Sebastianelli, CRNA have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.